How Emerging Biopharma Companies Can Successfully Launch Their Asset

Emerging biopharma (EBP) companies lack the resources of large pharma firms for pre-launch preparation and typically begin launch planning later, needing tailored, pragmatic prioritization. IQVIA deployed its Launch Excellence framework: a prioritization matrix assessing launch activities by impact and timeline criticality, a detailed Launch Excellence toolkit of cross-functional activities/resources/interdependencies, and a change-management roadmap addressing EBP-specific organizational challenges. No quantified results or performance metrics are given on the page.

The customer is anonymised in IQVIA’s own case study — not withheld by us.

IQVIA is the largest combined real-world-data and commercial-intelligence company in healthcare — its legacy IMS prescription and claims data underpins much of the industry's analytics.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.